ALPS Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$574K	Buy	+60,250	New	+$468K	﹤0.01%	676
2025 Q4	–	Sell	-101,125	Closed	-$768K	–	1021
2025 Q3	$768K	Sell	101,125 -11,710	-10%	-$97.5K	﹤0.01%	611
2025 Q2	$1.01M	Sell	112,835 -40,150	-26%	-$374K	0.01%	498
2025 Q1	$1.15M	Sell	152,985 -14,507	-9%	-$117K	0.01%	447
2024 Q4	$1.26M	Buy	167,492 +9,382	+6%	+$71.2K	0.01%	432
2024 Q3	$1.2M	Sell	158,110 -2,893	-2%	-$22K	0.01%	456
2024 Q2	$995K	Buy	161,003 +15,597	+11%	+$86.1K	0.01%	465
2024 Q1	$739K	Buy	145,406 +7,305	+5%	+$41.1K	0.01%	546
2023 Q4	$827K	Sell	138,101 -1,749	-1%	-$10.1K	0.01%	522
2023 Q3	$990K	Buy	139,850 +972	+0.7%	+$6.98K	0.01%	450
2023 Q2	$978K	Buy	138,878 +16,060	+13%	+$129K	0.01%	501
2023 Q1	$1.02M	Sell	122,818 -3,555	-3%	-$34.2K	0.01%	465
2022 Q4	$1.45M	Buy	126,373 +24,834	+24%	+$310K	0.01%	363
2022 Q3	$1.28M	Sell	101,539 -8,576	-8%	-$110K	0.01%	393
2022 Q2	$1.17M	Buy	+110,115	New	+$1.14M	0.01%	442
2018 Q2	–	Sell	-132,021	Closed	-$630K	–	931
2018 Q1	$630K	Buy	132,021 +22,977	+21%	+$118K	0.01%	408
2017 Q4	$535K	Buy	109,044 +29,841	+38%	+$145K	﹤0.01%	485
2017 Q3	$415K	Buy	79,203 +6,612	+9%	+$33.9K	﹤0.01%	692
2017 Q2	$404K	Buy	+72,591	New	+$442K	﹤0.01%	678
2016 Q2	–	Sell	-82,476	Closed	-$233K	–	612
2016 Q1	$233K	Sell	82,476 -14,134	-15%	-$62.6K	﹤0.01%	593
2015 Q4	$997K	Buy	+96,610	New	+$961K	0.01%	217